[Medical therapy of the metastasizing breast neoplasm].
For the metastasized breast cancer the indication for the ablative and additive hormonal treatment and/or for the combination chemotherapy is clearly outlined. The hormonal treatment should always be used first because of its good compatibility unless the prognostic assumptions are unfavorable, such as short intervals between primary treatment and recidivation or appearance of metastases and a visceral metastatic formation. In these cases a combination chemotherapy or a combined hormonal/cytostatic treatment should be applied. Various combination chemotherapy schedules are discussed and compared in regard to effectiveness, compatibility, side effects and dispensation. A final judgement for an additional immunological therapy and adjuvant chemotherapy of the pretreated breast cancer cannot be given.
D000315:Adrenalectomy; D000328:Adult; D000368:Aged; D000728:Androgens / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001500:BCG Vaccine; D001943:Breast Neoplasms / Q000628:therapy*; D004359:Drug Therapy, Combination; D004965:Estrogen Antagonists; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007016:Hypophysectomy; D008593:Menopause; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000628:therapy*; D010053:Ovary / Q000601:surgery; D011374:Progesterone / Q000627:therapeutic use
D000728:Androgens; D000972:Antineoplastic Agents, Phytogenic; D001500:BCG Vaccine; D004965:Estrogen Antagonists; D004967:Estrogens; D011374:Progesterone
Internistische Therapie des metastasierten Mammakarzinoms